Compare SPFI & PHAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SPFI | PHAR |
|---|---|---|
| Founded | 1941 | 1988 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 847.8M | 1.0B |
| IPO Year | 2019 | 2020 |
| Metric | SPFI | PHAR |
|---|---|---|
| Price | $43.60 | $11.48 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 3 |
| Target Price | ★ $46.00 | $38.33 |
| AVG Volume (30 Days) | ★ 89.7K | 22.5K |
| Earning Date | 04-28-2026 | 05-07-2026 |
| Dividend Yield | ★ 1.68% | N/A |
| EPS Growth | ★ 17.81 | N/A |
| EPS | ★ 1.82 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $22.65 | $10.04 |
| Revenue Next Year | $9.40 | $2.51 |
| P/E Ratio | ★ $23.99 | $3,041.22 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $35.34 | $9.62 |
| 52 Week High | $46.94 | $21.34 |
| Indicator | SPFI | PHAR |
|---|---|---|
| Relative Strength Index (RSI) | 42.60 | 45.69 |
| Support Level | $42.84 | $9.62 |
| Resistance Level | $44.08 | $13.51 |
| Average True Range (ATR) | 0.84 | 0.48 |
| MACD | -0.22 | 0.06 |
| Stochastic Oscillator | 28.92 | 6.41 |
South Plains Financial Inc operates as a bank holding company. The company provides a wide range of commercial and consumer financial services to small and medium-sized businesses and individuals. The principal business activities include commercial and retail banking, along with insurance, investment, trust, and mortgage services. The company has one reportable segment: banking. The majority of the company's revenues is derived from interest income and other sources, including loans, securities and derivatives.
Pharming Group is a biotechnology company focused on developing and commercializing therapies for rare and ultra-rare diseases, particularly immunological and genetic conditions with high unmet need. It operates as an integrated company with capabilities across clinical development, manufacturing, regulatory affairs, and commercialization, supported by scientific and operational expertise. It leverages its efficient infrastructure to expand its pipeline and improve patient access to treatment. The Company operates in the United States, Europe, and the rest of the world, with the United States contributing the majority of its revenue.